ENDRA LIFE SCIENCES INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
ENDRA LIFE SCIENCES INC. (NDRA) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $4.78 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-14
- ENDRA LIFE SCIENCES INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was -$405.90K.
- ENDRA LIFE SCIENCES INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$1.16M.
- ENDRA LIFE SCIENCES INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$1.70M.
- ENDRA LIFE SCIENCES INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$2.53M.
- ENDRA LIFE SCIENCES INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was -$2.47M, a 723.68% decline from fiscal 2024.
- ENDRA LIFE SCIENCES INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was $395.57K.
- ENDRA LIFE SCIENCES INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$2.06M.
- ENDRA LIFE SCIENCES INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$4.57M, a 304.65% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.78M 10-Q · filed 2026-08-14 | |||
| 2026-03-31 | -$405.90K 10-Q · filed 2026-05-15 | |||
| 2025-12-31 | -$2.47M 10-K · filed 2026-03-31 | |||
| 2025-09-30 | -$2.44M 10-Q · filed 2025-11-14 | |||
| 2025-06-30 | -$1.42M 10-Q · filed 2026-08-14 | |||
| 2025-03-31 | -$1.16M 10-Q · filed 2026-05-15 | |||
| 2024-12-31 | $395.57K 10-K · filed 2026-03-31 | |||
| 2024-09-30 | $1.91M 10-Q · filed 2025-11-14 | |||
| 2024-06-30 | $3.57M 10-Q · filed 2025-08-14 | |||
| 2024-03-31 | -$1.70M 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | -$2.06M 10-K/A · filed 2025-04-07 | |||
| 2023-09-30 | -$1.55M 10-Q/A · filed 2024-11-21 | |||
| 2023-06-30 | -$69.64K 10-Q · filed 2024-08-14 | |||
| 2023-03-31 | -$2.53M 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | -$4.57M 10-K · filed 2024-03-28 | |||
| 2022-09-30 | -$1.45M 10-Q · filed 2023-11-14 | |||
| 2022-06-30 | $1.82M 10-Q · filed 2022-08-15 | |||
| 2022-03-31 | -$2.33M 10-Q · filed 2022-05-12 | |||
| 2021-12-31 | $2.23M 10-K · filed 2023-03-16 | |||
| 2021-06-30 | $6.82M 10-Q · filed 2022-08-15 | |||
| 2021-03-31 | $9.62M 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | $1.05M 10-K · filed 2022-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRIDEX CORP (IRIX) | United States | $0.011B | |
| Nuwellis, Inc. (NUWE) | United States | $0.003B | |
| QT IMAGING HOLDINGS, INC. (QTI) | United States | $0.037B | |
| PRECISION OPTICS CORPORATION, INC. (POCI) | United States | $0.052B | |
| Outset Medical, Inc. (OM) | United States | $0.059B | -1.09 |
| Streamex Corp. (STEX) | United States | $0.089B | -0.19 |
| Nexalin Technology, Inc. (NXL) | United States | $0.094B | |
| Neuraxis, INC (NRXS) | United States | $0.097B | |
| electroCore, Inc. (ECOR) | United States | $0.102B | |
| Vivani Medical, Inc. (VANI) | United States | $0.111B |